Your browser doesn't support javascript.
loading
Multidisciplinary model to implement pharmacogenomics at the point of care.
Caraballo, Pedro J; Hodge, Lucy S; Bielinski, Suzette J; Stewart, A Keith; Farrugia, Gianrico; Schultz, Cloann G; Rohrer-Vitek, Carolyn R; Olson, Janet E; St Sauver, Jennifer L; Roger, Veronique L; Parkulo, Mark A; Kullo, Iftikhar J; Nicholson, Wayne T; Elliott, Michelle A; Black, John L; Weinshilboum, Richard M.
Afiliação
  • Caraballo PJ; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Hodge LS; Office of Information and Knowledge Management, Rochester, Minnesota, USA.
  • Bielinski SJ; Center for Individualized Medicine, Rochester, Minnesota, USA.
  • Stewart AK; Department of Health Sciences Research, Rochester, Minnesota, USA.
  • Farrugia G; Center for Individualized Medicine, Rochester, Minnesota, USA.
  • Schultz CG; Center for Individualized Medicine, Rochester, Minnesota, USA.
  • Rohrer-Vitek CR; Center for Individualized Medicine, Rochester, Minnesota, USA.
  • Olson JE; Center for Individualized Medicine, Rochester, Minnesota, USA.
  • St Sauver JL; Department of Health Sciences Research, Rochester, Minnesota, USA.
  • Roger VL; Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA.
  • Parkulo MA; Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA.
  • Kullo IJ; Office of Information and Knowledge Management, Rochester, Minnesota, USA.
  • Nicholson WT; Division of Community Internal Medicine, Jacksonville, Florida, USA.
  • Elliott MA; Division of Cardiovascular Diseases, Rochester, Minnesota, USA.
  • Black JL; Department of Anesthesiology, Rochester, Minnesota, USA.
  • Weinshilboum RM; Division of Hematology, Rochester, Minnesota, USA.
Genet Med ; 19(4): 421-429, 2017 04.
Article em En | MEDLINE | ID: mdl-27657685
ABSTRACT

PURPOSE:

Despite potential clinical benefits, implementation of pharmacogenomics (PGx) faces many technical and clinical challenges. These challenges can be overcome with a comprehensive and systematic implementation model.

METHODS:

The development and implementation of PGx were organized into eight interdependent components addressing resources, governance, clinical practice, education, testing, knowledge translation, clinical decision support (CDS), and maintenance. Several aspects of implementation were assessed, including adherence to the model, production of PGx-CDS interventions, and access to educational resources.

RESULTS:

Between August 2012 and June 2015, 21 specific drug-gene interactions were reviewed and 18 of them were implemented in the electronic medical record as PGx-CDS interventions. There was complete adherence to the model with variable production time (98-392 days) and delay time (0-148 days). The implementation impacted approximately 1,247 unique providers and 3,788 unique patients. A total of 11 educational resources complementary to the drug-gene interactions and 5 modules specific for pharmacists were developed and implemented.

CONCLUSION:

A comprehensive operational model can support PGx implementation in routine prescribing. Institutions can use this model as a roadmap to support similar efforts. However, we also identified challenges that will require major multidisciplinary and multi-institutional efforts to make PGx a universal reality.Genet Med 19 4, 421-429.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas Automatizados de Assistência Junto ao Leito / Prestação Integrada de Cuidados de Saúde Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas Automatizados de Assistência Junto ao Leito / Prestação Integrada de Cuidados de Saúde Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article